Our Finalists

This award recognizes companies with significant medical advances in dermatology.

Leader in Scientific Achievement


Allergan is a diversified global pharmaceutical company anchored by strong and sustainable brand franchises, a leading global generics business, and a premier pipeline. As well as its recent FDA approval for Juvederm Ultra XC for use in lips, Allergan has also recently received FDA approval for Dalvance and Teflaro, both for acute bacterial skin infections. Allergan acquired Kythera Biopharmaceuticals in October 2015, which is a biopharmaceutical company focused on the discovery, development, and commercialization of novel prescription products for the aesthetic medicine market. The FDA recently approved its lead product Kybella, which is a non-surgical treatment for contouring moderate to severe double chins.


Galderma is a global dermatology company committed to delivering innovative medical dermatological solutions that meet the needs of both patients and physicians, with a particular focus on acne, rosacea, psoriasis, and other steroid-responsive dermatoses, onychomycosis, pigmentary disorders, skin cancer, and medical aesthetic and corrective solutions for skin senescence. Galderma recently launched Restylane Silk, a dermal filler approved by the FDA for lip enhancement and the treatment of wrinkles and lines around the mouth in people over the age of 21. Galderma also recently received FDA approval for Epiduo Forte gel, a new antibiotic-free treatment option for acne, and for Soolantra Cream, 1%, for the once-daily topical treatment of inflammatory lesions, or bumps and pimples, of rosacea.

Bristol-Myers Squibb

Bristol-Myers Squibb is a global BioPharma company focused on its mission to discover, develop, and deliver innovative medicines for patients with serious diseases. Around the world, its medicines help millions of people in their fight against such diseases as cancer, cardiovascular disease, hepatitis B and hepatitis C, HIV/AIDS, and rheumatoid arthritis; and it has delivered 12 new medicines in the past 7 years. Bristol-Myers Squbb received FDA approval for Opdivo (nivolumab), a new treatment for patients with unresectable (cannot be removed by surgery) or metastatic (advanced) melanoma who no longer respond to other drugs.


Novartis is a global healthcare company based in Switzerland that provides solutions to the evolving needs of patients worldwide. This year it received FDA approval for Cosentyx (secukinumab) for the treatment of adults with moderate-to-severe plaque psoriasis. In addition, Novartis drug Odomzo (sonidegib) recently gained EU and FDA approval for the treatment of locally advanced basal cell carcinoma, providing new non-invasive therapy for patients.

Online Voting

NOV 17 - DEC 4, 2015

Vote for the Leaders of Distinction in Dermatology

Winners Announced

WEEK OF DEC 14, 2015

Award Ceremony

JAN 15 - 18, 2016

Orlando Derm Aesthetic & Clinical Conference
Omni Orlando Resort, Championsgate, FL.